Browse drugs

…tion was 87.3±106.1 µm with aflibercept and 113.1±136.7 µm with faricimab. Adjusted mean reductions were 95.4 µm and 99.8 µm, respectivel…

…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …

… All patients were switched. Thirty eyes received three or more faricimab injections as a loading phase, ten received a single dose and n…

…ti-angiogenic therapy, mainly aflibercept and bevacizumab, with faricimab as a second-line option. Personalised treatments and optimised …

…tments that provide both high efficacy and extended durability. Faricimab, a bispecific antibody targeting VEGF-A and Ang-2, offers the p…

…f the study.Conclusion and Relevance Centralised compounding of faricimab syringes led to substantial cost savings in public healthcare, …

…tients (10 injections); faricimab 94 patients (321 injections); ranibizumab 37 patients (127 injections).Classified by most frequent diagno…

…) SRF only 19 11 (57.89%) 2 of 8 (25%) Conclusion and Relevance Faricimab enabled dosing interval extension and improved retinal anatomy …

…low number of AEs supports a favourable risk-benefit profile of faricimab in a real-world setting.…

…cizumab MVASI (25 mg/mL), ranibizumab Ranivisio (0.6 mg/mL) and faricimab Vabysmo (120 mg/mL) stored in silicone-free and oil-free polypropylene …

…r centre’s experience.Aim and Objectives To evaluate the use of faricimab and its economic impact from the hospital pharmacy perspective.…

… patients currently treated for nAMD who switch to intravitreal faricimab therapy under a treat-and-extend regimen.Methods and analysis T…